Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH for Diagnostic Scanning in Differentiated Thyroid Cancer
NCT04971473Phase 3Completed
- Sponsor
- Zelgen
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of thyrotropin alfa in differentiated thyroid cancer (DTC), sponsored by Zelgen. Primary endpoint: The rate of concordant scans. Started Sep 2021; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04971473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971473.